ArticleCureus2025
Eosinophilic Fasciitis: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review.Rheumatology international · 2026Pooled it
- [Shulman syndrome: An atypical presentation of a rare disease].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Recurrent Eosinophilic Fasciitis: The First Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic fasciitis (EF) is a rare and frequently underdiagnosed condition, with limited representation in the scientific literature. Early and accurate diagnosis is critical to preventing the progression of the disease and the development of irreversible damage. EF is characterized by thickening and fibrosis of the subcutaneous fascia and skin, typically affecting the extremities, trunk, and neck, with peripheral eosinophilia occasionally observed. While most cases are considered idiopathic, a thorough evaluation is essential to rule out differential diagnoses or associated underlying conditions. The disease significantly impacts patients' daily activities and is associated with substantial morbidity. Management of EF primarily involves the use of corticosteroids and other immunosuppressive therapies. The majority of patients demonstrate favorable responses to treatment, particularly when intervention occurs before the onset of advanced fibrosis. In this paper, we present a case series involving four patients diagnosed and treated at our institution. We provide a detailed analysis of the diagnostic process, therapeutic approaches, and follow-up strategies employed, contributing to the broader understanding of this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.